<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742623</url>
  </required_header>
  <id_info>
    <org_study_id>18137</org_study_id>
    <secondary_id>XA1502</secondary_id>
    <nct_id>NCT02742623</nct_id>
  </id_info>
  <brief_title>A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer</brief_title>
  <acronym>COSIMO</acronym>
  <official_title>COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to XareltoÂ® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to collect patient reported outcomes and assess treatment satisfaction in
      active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Anticipated">March 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment satisfaction burden score (ACTS)</measure>
    <time_frame>At 4 weeks</time_frame>
    <description>Patient reported treatment satisfaction will be assessed with regard to the Anti-Clot Treatment Scale (ACTS) burden score for the use of rivaroxaban for treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in patients with active cancer changing to this therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preferences regarding the attributes of the anticoagulation medication options LMWH, VKA, rivaroxaban using DCE survey</measure>
    <time_frame>Between 4 weeks and 3 months</time_frame>
    <description>Discrete Choice Experiment (DCE) based preference of patients for rivaroxaban versus other anticoagulants in a semi-structured telephone interview
LMWH: Low Molecular Weight Heparin; VKA: Vitamin K Antagonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ACTS score over time</measure>
    <time_frame>At 3 months and 6 months</time_frame>
    <description>To assess patient reported outcomes by means of the Anti-Clot Treatment Scale (ACTS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life using the FACIT-Fatigue questionnaire</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To assess patient reported outcomes on quality of life using the FACIT-Fatigue questionnaire (Functional Assessment of Chronic Illness Therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of index VTE (venous thromboembolism) event</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of index VTE event</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type (trade name) of initial anticoagulation treatment</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of initial anticoagulation treatment</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for drug switch to rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
    <description>Menu items: patient choice, physician choice, side effects, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned duration of anticoagulation with rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual duration of anticoagulation with rivaroxaban</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of rivaroxaban</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for any potential dose adjustments during course of treatment with rivaroxaban</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Menu items: side effects, intervention, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for any switch from rivaroxaban treatment</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Menu items: patient choice, physician choice, side effects, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for permanent cessation of rivaroxaban treatment</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Menu items: patient choice, physician choice, side effects, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNM Staging (Clinical characteristics of cancer disease)</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment according to TNM (Tumor, Lymph Node and Metastases) classification. TNM is developed and maintained by the Union for International Cancer Control (UICC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary site of cancer (Clinical characteristics of cancer disease)</measure>
    <time_frame>At baseline</time_frame>
    <description>Following Medical Dictionary for Regulatory Activities (MedDRA) coding system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of bleeding events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of thromboembolic events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of thromboembolic events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Venous Thrombosis and Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY 59-7939)</intervention_name>
    <description>Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male patients with active cancer and a diagnosis of DVT/ and/or PE after the
        decision for treatment with rivaroxaban
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female and male patients with active cancer other than fully treated basal-cell
             or squamous-cell carcinoma of the skin (active cancer defined as the diagnosis or
             treatment of cancer in the previous &lt; 6 months or recurrent or metastatic cancer)

          -  Patients that have been treated with standard of care anticoagulation (Low Molecular
             Weight Heparin / Vitamin K Antagonist) for treatment of DVT and/ or PE (index VTE
             event) and/ or prevention of recurrent DVT and PE for at least 4 weeks prior to
             inclusion in the study

          -  Patients for whom the decision was made to start rivaroxaban for treatment of DVT and/
             or PE and/ or prevention of recurrent DVT and PE

          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0,
             1 or 2

          -  Patients who are willing to participate in this study (signed informed consent)

          -  Patients who are available for follow-up with a life expectancy &gt;6 months

        Exclusion Criteria:

          -  The contra-indications according to the local marketing authorization must be
             considered

          -  Patients who developed an index VTE event despite chronic anticoagulant therapy

          -  Patients receiving apixaban, edoxaban or dabigatran or any investigational drug as the
             initial therapy for the index VTE event

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice with exception of oncology investigational trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Deep Venous Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

